MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis

doi:10.21203/rs.3.rs-1538869/v1

Download PDF

Research Article

MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis

https://doi.org/10.21203/rs.3.rs-1538869/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 04 Jan, 2023

Read the published version in Molecular Cancer →

You are reading this latest preprint version

Background: Small cell lung cancer (SCLC) is an aggressive lung cancer subtype that is associated with high recurrence and poor prognosis. Due to a lack of potential drug targets, SCLC patients have few therapeutic options. MicroRNAs (miRNAs) provide an interesting repertoire of therapeutic molecules; however, the identification of miRNAs regulating SCLC growth and metastasis and their precise regulatory mechanisms are not well understood.

Methods: To identify novel miRNAs regulating SCLC, we performed miRNA-sequencing from donor/patient serum samples and analyzed the bulk RNA-sequencing data from the tumors of SCLC patients. Further, we developed a nanotechnology-based, highly sensitive method to detect miR-1 (identified miRNA) in patient serum samples and SCLC cell lines. To assess the therapeutic potential of miR-1, we developed various in vitro models, including miR-1 sponge (miR-1Zip) and a DOX-On-miR-1 (Tet-ON) inducible stable overexpression systems. Mouse models derived from intracardiac injection of SCLC cells (miR-1Zip and DOX-On-miR-1) were established to delineate the role of miR-1 in SCLC metastasis. In situ hybridization (ISH) and immunohistochemistry (IHC) were used to analyze the expression of miR-1 and target proteins (mouse and human tumor specimens), respectively. Dual-luciferase assay was used to validate the target of miR-1, and ChIP-assay was used to investigate the protein-gene interactions.

Results: A consistent downregulation of miR-1 was observed in tumor tissues and serum samples of SCLC patients compared to their matched normal controls, and these results were recapitulated in SCLC cell lines. Gain of function studies of miR-1 in SCLC cell lines showed decreased cell growth and oncogenic signaling, whereas loss of function studies of miR-1 rescued this effect. Intracardiac injection of gain of function SCLC cell lines in the mouse models showed a decrease in the distant organ metastasis, whereas loss of function of miR-1 potentiated growth and metastasis. Mechanistic studies revealed that CXCR4 is a direct target of miR-1 in SCLC. Using un-biased transcriptomic analysis, we identified CXCR4/FOXM1/RRM2 as a unique axis that regulates SCLC growth and metastasis. Our results further showed that FOXM1 directly binds to the RRM2 promoter and regulates its activity in SCLC.

Conclusions: Our findings revealed that miR-1 is a critical regulator for decreasing SCLC growth and metastasis. It targets the CXCR4/FOXM1-RRM2 axis and has a high potential for the development of novel SCLC therapies.

Small cell lung cancer

microRNAs

CXCR4

FOXM1

RRM2

neuroendocrine carcinoma

Small cell lung cancer (SCLC) is a metastatic neuroendocrine disease that remains among the most lethal type of solid tumors [1]. Initially, SCLC respond to conventional chemotherapy (cisplatin/carboplatin/etoposide), with a response rate of ~ 60–70%; however, the majority of the SCLC patients develop resistance to front-line therapies, experience relapse, and die in a matter of months [2, 3]. Due to high metastasis, late diagnosis, and recalcitrant behavior of SCLC, a limited number of therapies are available and despite the incorporation of immunotherapy to platinum-based front-line therapies, improvements in overall survival or outcomes of SCLC remain modest [4–6].

Identifying potential therapeutic targets in SCLC remains challenging. A major limiting factor is the high mutational load leading to the inactivation or deletion of two major tumor suppressor genes (RB1 and TP53) [7, 8]. Along with the dysregulation of protein-coding genes, non-coding genes also found dysregulated in various cancer types, including SCLC [9]. Since only 2% of transcribed genes encode functional proteins; and the untranslated genes constitute a major part of the human genome with important gene regulatory roles [9]. One such important class of genes encodes microRNAs (miRNAs); these are the small nucleotide sequences with a key regulatory impact on gene expression [10, 11]. The miRNAs bind to complementary sequences on the target mRNA to preclude translation through a sequence-specific RNA-interference (RNAi) mechanism [11]. Simultaneously, a single miRNA can have multiple genomic targets and multiple miRNAs regulate one or more hallmarks of cancer; thus, microRNAs have the potential to regulate different molecular pathways [12, 13]. More than 2800 mature human miRNA sequences are currently annotated in public databases like miRBase V22, and their sequences are evolutionarily conserved [14].

Interestingly, miRNAs can behave as tumor suppressors and tumor promoters [15, 16]. Several studies have demonstrated that miRNAs regulate cell viability, growth, migration, angiogenesis, and apoptosis [17]. As single miRNA can regulate the expression of different genes at transcriptional or translational levels, they provide a valuable platform to investigate the role of miRNAs and their targets in the pathogenesis of various cancers, including SCLC. In the present study, employing miRNA sequencing and various screening analyses, we identified and rationalized the investigation of tumor suppressor microRNA-1 (miR-1) in SCLC. Previously, miR-1 has been reported to play a major role in cardiomyocyte differentiation and smooth muscle development [18, 19]. MiR-1 is highly conserved throughout the mammalian system and acts as a consistent tumor suppressor gene [18, 20]. However, the impact of miR-1 on SCLC pathogenesis remains unexplored. Here, we profile miR-1 expression and functional outcomes in SCLC and show that miR-1 downregulation is associated with SCLC growth and metastasis. Further, we investigated CXCR4/FOXM1/RRM2 axis as a novel target of miR-1 both in vitro and in vivo. Its overexpression or targeted delivery can be a potential therapeutic strategy to improve the outcomes of SCLC.

Cell lines and maintenance

The human SCLC cell line SBC3 was gifted by Dr. Takashi Kijima (Osaka University, Japan), and SBC5 was obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan. BEAS-2B, DMS273, DMS53, NCI-H82, NCI-H526, NCI-H69 and Colo668 were originally obtained from ATCC (Rockville, MD, USA). All the cell lines were routinely maintained and cultured in standard culture conditions, in a CO₂ incubator at 37°C, and regularly validated using STR profiling and checked for mycoplasma infections prior to experiments. For routine maintenance, SBC3, SBC5, NCI-H82, NCI-H69, NCI-H526, DMS273, DMS53, and Colo668 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Sigma Cat#12303C), 1% penicillin/streptomycin cocktail solution (Invitrogen Cat#15140-122), 1% sodium pyruvate (Invitrogen Cat#11360070), and 1% L-glutamine (Invitrogen Cat#25030-081).

DNA-AuNPs nanoprobe for the detection of miR-1 in serum and cell lines

Except for the cell-isolated total RNA sample, the in situ (RNA isolation-free) detection of the serum miRNA was performed after treating the serum with the denaturation buffer (1X TAE buffer, 2.0 M NaCl, 10% IGEPAL CA-630, 0.01U/µL RNase inhibitor, 40µg of proteinase K (from a 20mg/mL stock). The denaturation step ensured that serum miRNAs were freed from transport vesicles/exosomes and stabilizing AGO2 protein complexes, and it denatured the background proteins [21, 22]. Briefly, the serum samples were incubated for 30 min in an equal volume of denaturation buffer and heated to 95°C for 5 min. The protein pellet was removed by quick centrifugation (6000 rpm, 6 min, room temperature). Samples representing a starting serum volume of 20 µl were reacted with 10 nM of DNA-AuNP, DSN enzyme (0.03 U/µL) in DSN buffer (50 mM Tris-HCl, 5 mM MgCl₂, 10 mM DTT, RNase inhibitor 0.01U/µL pH 8.0) in a 50 µL volume (384-well) overlaid with silicone oil (6µL). In the same plate, we also quantified the known concentrations of the synthetic miR-1 oligos (2.5–1000 pM) to construct a standard curve representing miR-1 concentration using the optimized conditions and instrumental settings as mentioned in Table S4. Finally, to estimate the miR-1 concentration, the increased fluorescence intensity slope (before reaching signal plateau) was determined and compared with the standard curve (fluorescence ratio (F/F₀-1) vs. [miR-1]).

In-situ hybridization

The expression level of miR-1 was determined by employing in situ hybridization (ISH). For this, we used a commercially available, single-color human or mouse-specific 20-paired double-Z oligonucleotide miR-1 probe (Advanced Cell Diagnostics) as described previously [23]. The images were captured using a 40x and 100x Bright-field objective.

Lentivirus production

Lentivirus was generated using the Lipofectamine-2000 co-transfection method in HEK293T cells. Briefly, the respective lentivirus-based expression vectors of miR-1, miR-1Zip, and control vector were co-transfected with packaging vectors from Addgene; pMDLg/pRRE #12251, pRSV-Rev #12253, and envelope expressing plasmid pMD2.G #12259. Culture supernatant containing lentiviral particles was collected after 48h and 72h of transfection, centrifuged to clear the cell debris, filtered through 0.45-micron sterile filters, aliquoted, and stored at -80⁰C until used.

Generation of miR-1 inducible and miR-1Zip system

Stable expression clones of miR-1 were generated in SBC5 and NCI-H69 cell line using 3rd generation lentiviral system. We performed a dual transduction method using rtTA along with pLV[Tet]mCherry:T2A:Puro > TRE3G > FLAG/hmiR-1/HA:T2A:Luciferase or pLV[Tet]-mCherry:T2A:Puro > TRE3G->Luciferase vectors, procured from VectorBuilder, TX. The expression vector consecutively expresses mCherry, whereas the luciferase expression is under the Tet-inducible promoter's control and used for in vivo imaging. Nearly 1 × 10⁵ SBC5 or NCI-H69 cells were seeded in a six-well plate and transduced with lentiviral particles (with 8 µg/ml polybrene) for transduction. After 24–48 h incubation, the transduced cells were replenished with a fresh cell culture medium. The transduction efficiency was monitored by visualizing the cells for mCherry expression using fluorescence microscopy. Finally, the positive mCherry cells were sorted on FACS Aria II (B.D. Biosciences), and consequently transduced with rtTA-lentiviral particles (for the doxycycline-induced activation of TRE3G promoter by the transactivator Tet3G). The anti-miR-1 microRNA (miR-1Zip) lentivirus expression vector was obtained from System Biosciences, California, USA (miRZip-1 anti-miR-1 microRNA construct, Catalogue # MZIP1-PA-1, having T2A: Puro > CMV:copGFP > H1:miRZip-1 anti-miR-1), which was transduced in SBC3 cell lines, as described above.

Small RNA library preparation and miRNA sequencing from serum samples of SCLC patients

The cell-free total RNA, including miRNAs was isolated using miRNeasy serum/plasm kit (Qiagen, Germantown, MD, Cat # 217184) by following the manufacturer’s protocol. All libraries were prepared using the Illumina TruSeq Small RNA protocol with minor modifications following the manufacturer’s instructions with 12 cycles of PCR amplification after ligation of the 3′ and 5′ adapters. This protocol is ideal for the investigation of small RNA species, as it takes advantage of the structure of most small RNA molecules by ligating specific adapters to the 5′-phosphate and 3′-hydroxyl group, which are molecular signatures of their biogenesis pathway. Individual libraries were prepared using a unique index primer to allow for the pooling of multiple samples prior to sequencing. The library was quantified using qPCR. Sequencing was performed on a Hiseq2500 (Illumina Inc., San Diego, CA), and image processing and base calling were conducted using Illumina's pipeline.

RNA-sequencing and deferential gene expression analysis

SBC3/SBC3-miR-1Zip, SBC5/SBC5-miR-1-Tet-ON (-DOX/+DOX) cells were lysed using RNA lysis buffer provided with the mirVana RNA isolation kit (Thermo Scientific Fischer). Total RNA was isolated by following the manufacturer’s protocol. Whole transcriptome analysis (RNA sequencing) was performed on SBC3/SBC3-miR-1Zip, SBC5/SBC5-miR-1-Tet-ON (-DOX/+DOX) cells at Sequencing Core Facility, City of Hope Comprehensive Cancer Center and Beckman Research Institute. RNA quality was determined using Agilent Bioanalyzer (Agilent Technologies, Inc.) and RNA samples with integrity numbers (RINs) of 10 were used for further analyses. Library preparation, PCR amplification, size distribution, library quantification, and sample loading were performed as described previously [24]. Sequencing was performed on a HiSeq2500 sequencer (Illumina Inc., San Diego, CA) in rapid mode. A single read, 50 cycle, sequencing run and onboard clustering and V2 chemistry were used. Raw files for RNA-seq were submitted to GEO (accession number GSE0000000).

Chromatin immunoprecipitation and qPCR

Chromatin immunoprecipitation (ChIP) was performed with minor modifications [25]. Briefly, 15 x 10⁶ cells were cross-linked with 1% formaldehyde for 10 min at room temperature. The cross-linking was stopped by adding 0.125 M glycine for 5 min, and cells were washed with chilled PBS (2X), scraped, and collected by centrifugation (820 x g, 5 min, 4°C). The enriched ChIP DNA was analyzed by quantitative real-time PCR using Syber green on the CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA). The primers used in the study are-P1 F/R, P2 F/R, P3 F/R, and P4 F/R (details provided in supplementary information). The coimmunoprecipitated gene fragments were represented as a fold enrichment method based on Ct values (2^{-(Ct(FOXM1 IP) – Ct(IgG))}).

CXCR4 3'-UTR dual luciferase assay

CXCR4 3'-UTR luciferase assay was performed as described previously [26]. Following 48h of CXCR4 3'-UTR-wild-pGL3/3'-UTR-mutant-pGL3 transfection, luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI) using a Luminometer (Agilent, Biotek, CA, USA).

SCLC cell line xenografts studies

SBC3 and SBC3-miR-1Zip cells were transduced with firefly luciferase-expressing construct and resuspended at 3 × 10⁷ cells/ml in PBS. Nearly 3 × 10⁶ cells (SBC3 or SBC3-miR-1Zip) were implanted subcutaneously into bilateral flanks of 8-week-old NSG mice (both male and female). The mice were followed and monitored daily, and tumor growth was followed by an IVIS imaging system and caliper-based measurements. The tumor volume measurements were carried out using the relation: tumor volume (mm³) = (tumor width)²× length/2. All mouse experiments/procedures were duly approved and performed as per Institutional animal care and use committee (IACUC) guidelines in accordance with the National Institute of Health (NIH). The animals were maintained as per IACUC guidelines in the University of Nebraska medical center (UNMC) animal house facility.

Intracardiac injections

a) SBC3 and SBC3-miR-1Zip cells

To determine the impact of miR-1 inhibition on the metastatic potential of SCLC cells, intracardiac injections of SBC3 and SBC3-miR-1Zip cells were performed as described previously [23]. Briefly, 1x10⁵ SBC3-luciferase or SBC3-miR-1Zip-luciferase cells were injected into the left ventricle of female or male NSG mice. The mice were monitored weekly for metastases through luciferase-luciferin bioluminescence measurement using an IVIS imaging system. Before imaging, luciferin (150 mg/kg in sterile PBS) was injected intraperitoneally. Reaching the experiment endpoint (~ 6 weeks), mice were euthanized, and all major organs (lung, liver, spleen, brain, pancreas, intestine, adrenal, ovary, hindlimb bones) were harvested within 10 min of luciferin injection, and ex-vivo IVIS imaging was performed to see metastasis through luciferin-luciferase bioluminescent imaging. Serum was obtained from the collected blood after a cardiac puncture at the time of sacrifice for analyzing miR-1 expression.

b) miR-1 inducible SBC5 cells

To study the impact of miR-1 overexpression on SCLC growth and metastasis, intracardiac injections of Tet inducible miR-1 overexpressing SBC5 cells were performed. Briefly, 1x10⁵ SBC5 (-DOX-off)/SBC5-DOX-On-miR-1 cells were injected into the left ventricle of NSG mice (both male and female). After two weeks of intracardiac injections, mice were randomized into two groups, -DOX (without doxycycline) and + DOX (with doxycycline). In the case of + DOX animal group, mice were kept on special DOX feed (ENVIGO, Cat#TD.08541, Rodent Diet 2018, 625 Dox, R) or water (doxycycline, 3.2 g/liter, and sucrose 30 g/liter) to induce miR-1 overexpression whereas -DOX mice are on respective control diet (ENVIGO, Cat#TD.00588, Global 18% Protein Rodent Diet-Control). The doxycycline-sucrose solution was changed every 2 to 3 days throughout the experiment. The metastases were monitored through luciferin bioluminescence measurement of luciferase-expressing cells using the IVIS system. Luciferin (150 mg/kg in sterile PBS) was injected intraperitoneally before imaging. Serum was obtained from the collected blood after a cardiac puncture at the time of sacrifice for analyzing miR-1 expression.

Survival studies

A total of 20 mice (both male and female) intracardially injected with SBC5 (-DOX-off)/SBC5-DOX-On-miR-1 were randomized and switched to DOX diet (with miR-1) or -DOX (without miR-1) groups, and the survival of mice was monitored for nearly six months. Kaplan-Meier survival estimate was used to determine the median overall survival, and the statistical significance was ranked by P-value < 0.05.

Statistical analysis

All graphs were presented as mean ± SEM unless otherwise indicated. The statistical tests to perceive the differences between the two groups were implemented using a two-tailed unpaired Student t-test or a two-tailed Mann–Whitney test (as specified in the respective figure legends). The Kaplan-Meier method and Log-rank test were used for the miR-1 mediated mouse survival analyses. P values were considered significant if less than 0.05. The asterisks used to specify significance correspond with *, P < 0.05; **, P < 0.01; *** P < 0.001; ****, P < 0.0001.

Overall microRNA expression landscape in SCLC identifies miR-1 as a tumor suppressor gene in SCLC

MicroRNAs or non-coding RNAs are important molecules that regulate the expression pattern of multiple genes, including tumor suppressors and tumor promoters [27, 28]. Therefore, apart from identifying protein targets, microRNAs also provide a means to identify molecules modulating the various aspects of cancer and putting forward the potential of identifying tumor suppressor microRNAs as a useful strategy to develop or identify novel therapeutic agents. To understand the expression profile of microRNAs in SCLC, we performed miRNA sequencing from serum samples of eight SCLC patients and six healthy donors. The advantage of using serum samples is the secretory nature of miRNAs, which exist in exosomes and argonaute (AGO) proteins in circulation/serum that can be easily detected using noninvasive techniques [22, 29, 30]. We observed a differential expression pattern of miRs (65 up/13 down) in SCLC/donor serum samples, and interestingly, we observed a significant downregulation of miR-1 in the SCLC patients compared to healthy donors (Fig. 1A-C, supplementary Fig. S1A-C). To further understand miR-1 expression in SCLC and to validate the observation of miRNA-Seq, we also performed a bulk RNA-Seq analysis in the tumor tissues of SCLC patients and normal lung tissues (GSE19945). We observed a substantial downregulation of miR-1 in the SCLC tumors compared to normal lung tissues (Fig. 1D).

Further, to analyze the miR-1 expression in SCLC, we developed an advanced and highly sensitive nanoprobe-based biosensing assay that performs the absolute quantification of miR-1 in serum or cell line samples (Fig. 1E). For this, we synthesized and characterized a DNA-probe-functionalized Au-nanoprobe (DNA-AuNPs) that can be used to detect miR-1 from cell-derived total RNA or directly from serum or plasma. The synthesis and characterization are provided in supplementary information and supplementary figures S2-S3. Given that most of the miRNAs exist with AGO2 protein forming a RNA-induced silencing complex (RISC) and exosomes [22, 30], we performed a gold nanoprobe-mediated in situ (RNA isolation free) detection of miR-1 in the serum samples of human SCLC patients and healthy donors (Fig. 1F). Notably, to enhance the accuracy of serum miRNAs assay, a protein denaturation step was performed using a short treatment of the denaturation buffer on the serum followed by heat inactivation and removal of excess proteins (for details, see supplementary information) to facilitate the availability of miRNAs for biosensing purpose. Interestingly, we observed that miR-1 expression was drastically decreased in the serum samples of SCLC compared to healthy donors (Fig. 1F).

In addition, to determine the clinical significance of miR-1 expression, we performed in-situ hybridization on SCLC tissue microarray (Cat#, BS04116a, US Biomax, Inc. Derwood, MD), representing the pathology grade tumor tissues of 55 cases/100 cores for SCLC and ten cores for normal lung tissues. Using a miR-1 specific probe, the in-situ hybridization results validated the observations of miRNA-Seq and miR-1 serum profiling data that showed decreased expression of miR-1 in SCLC tumor tissues compared to normal lung tissues (Fig. 1G). Further, to determine miR-1 expression in SCLC cell lines, we performed a Taq-man-based miR-1 expression assay using a panel of SCLC cell lines (SBC3, SBC5, DMS273, NCI-H526, NCI-H82, DMS53, NCI-H69, and Colo668) and non-tumorigenic lung epithelial cells (BEAS-2B). Consistent with the bulk gene expression data, serum miRNAs sequencing, and nanoprobe-mediated expression profile of serum miR-1, a decrease to the null expression of miR-1 was observed in SCLC cell lines compared to non-tumorigenic lung epithelial cells (Fig. 1H). Together, our results suggest that downregulation of miR-1 accompanying SCLC, and consistent with the previous studies in other cancers [20, 31], establishes miR-1 as a tumor suppressor in SCLC.

miR-1 overexpression decreases the growth and metastasis of SCLC cells, whereas miR-1 inhibition potentiates cell growth and migration of SCLC cells

To investigate the role of miR-1 in the growth and metastasis of SCLC cells, we infected miR-1 expressing cell line (SBC3) with lentivirus containing miR-1Zip-GFP that was used to develop stable knockdown in the SBC3 cell line. For making a stable miR-1 overexpression model, we infected two miR-1 null SCLC cell lines (SBC5 and NCI-H69) with lentivirus that constitutively expresses mCherry and doxycycline (DOX) inducible miR-1 and luciferase expression. We have selected the positive clones using puromycin selection and single-cell sorting using GFP (for miR-1Zip) or mCherry (for DOX-On-miR-1) as markers. The DOX-On-miR-1 cells were further infected with lentivirus expressing rtTA having hygromycin as a selectable marker. In all the experiments, lentiviral-infected cells were maintained under the selection of the drug (puromycin/hygromycin) suitable for the corresponding lentiviral vector.

Before starting the functional studies, we first determined the miR-1 expression using miR-1 specific Taq-man qRT assay in SBC5-DOX-On miR-1 cells and observed that these cells showed significant upregulation in miR-1 expression following the 24–48 h induction with DOX compared to non-induced (-DOX-off) SBC5 cells (Fig. 2A). To monitor the effect of miR-1 on SCLC cells, SBC5-DOX-On miR-1 cells were plated in a low attachment cell culture plate and allowed to form spheres. We monitored and analyzed the growth of spheres formed by SBC5 (-DOX-off) Vs. SBC5-DOX-On miR-1 cells, and as expected [31, 32], once we induced miR-1 expression in SBC5 cells using DOX-On miR-1, it suppressed the sphere formation ability of SBC5 cells (Fig. 2B). In a complementary set of experiments on SBC3 and SBC3-miR-1Zip cells, it was found that miR-1 sponging (via miR-1Zip) supported the sphere-forming ability of SBC3 cells compared to parental SBC3 cells (Fig. 2C). In another variation of cell growth experiments, we also examined the role of miR-1 in colony formation by SCLC cells and found that miR-1 overexpression significantly decreased the colony formation in SBC5 cells, whereas SBC3-miR-1Zip cells had a higher colony-forming ability compared to parental cells (Fig. 2D-E).

Next, to see the impact of miR-1 on the migration properties of SCLC cells, we employed a live cell monitoring approach using IncuCyte coupled live-cell imaging. We seeded the SBC5(-DOX-off)/SBC5-DOX-On-miR-1 and SBC3/SBC3-miR-1Zip cells in a 96-well plate and simultaneously created a homogenous wound using the wound creating apparatus. We followed wound closure ability of SBC5(-DOX-off)/SBC5-DOX-On-miR-1 (without or with miR-1) and SBC3/SBC3-miR-1Zip cells in real-time for 72 h and found that miR-1 decreased the wound closure ability of SBC5 cells, and miR-1 sponging enhanced the wound closure or migratory properties of SBC3 cells as revealed by live-cell monitoring, scratch wound assay, and transwell migration studies (Fig. 2F-G & supplementary Fig. S4 A-D). We were then interested in discerning the apoptotic potential of miR-1 in SCLC cells (SBC5 and NCI-H69). For this, the DOX-On-miR-1 SBC5 and NCI-H69 cells were plated, and miR-1 expression was induced (+ DOX) for the different time periods (24–72 h), and apoptosis quantification was performed through flow cytometry-based annexin-V/PI staining. We observed that miR-1 overexpression induced apoptosis-like morphological changes in the SCLC cells (supplementary Fig. S5A-B). Further, we found a time-dependent significant increase in the percent apoptosis of miR-1 induced SBC5 and NCI-H69 cells compared to their -DOX-off controls (Fig. 2H-J). Thus, overall results showed that miR-1 decreased the sphere formation and cell migration properties of SCLC cells and induced apoptosis; on the other hand, miR-1 sponging enhanced sphere-forming and cell migration abilities of SCLC cells.

miR-1 modulates tumor growth and metastasis in SCLC xenografts

To probe deeper into the role of miR-1 in SCLC growth and metastasis, we performed tumorigenesis and metastasis studies with luciferase labeled SBC3 and SBC3-miR-1Zip cells using subcutaneous and intracardiac xenograft models in immunodeficient NOD/SCID gamma (NSG) mice (Fig. 3A). For tumorigenesis, the SBC3-luciferase and SBC3-miR-1Zip-luciferase cells were subcutaneously injected into the right flank of NSG mice (n = 6 per group with equal number of male and female mice) and monitored for tumor growth using IVIS-imaging (Fig. 3B). We found that the growth of SBC3-miR-1Zip xenografts was significantly higher compared to SBC3-parental cells suggesting that miR-1 sponging enhanced the tumorigenesis of SBC3 cells (Fig. 3C-E).

To determine the effect of miR-1 sponging on the metastatic potential of SCLC cells, we injected SBC3-luciferase and SBC3-miR-1Zip-luciferase cells intracardially in NSG mice, and we observed higher metastases in animals injected with SBC3-miR-1Zip cells (Fig. 3F). Remarkably, significant metastasis was observed in the liver, lung, intestine, ovary (female mice), and adrenal glands of mice injected with SBC3-miR-1Zip-luciferase cells (Fig. 3F-G). Lung, liver, ovary, and adrenal glands are the most common metastatic sites for SCLC [33, 34]. Further, IHC staining analysis of SBC3/SBC3-miR-1Zip-xenografts tumors with the proliferative and angiogenesis marker (Ki67 and CD31, respectively) revealed high Ki67 and CD31 staining in SBC3-miR-1Zip tumor tissues compared to SBC3 parental (Fig. 3H). These results suggest that miR-1 inhibition drives a highly metastatic SCLC phenotype in an intracardiac xenograft mouse model.

Next, to elucidate the impact of miR-1 overexpression on SCLC metastasis, we performed intracardiac injection of -DOX-off/DOX-On-miR-1 SBC5 cells (highly metastatic and relatively low miR-1 expression) in NSG mice (both male and female). Following two weeks of intracardiac injections, mice were randomized into (+)miR-1/DOX-On and (-)miR-1/-DOX-off groups (Fig. 4A). The metastatic lesions were monitored using IVIS-imaging (Fig. 4B &C). Consistent with the metastatic phenotype of SBC5 cells, intracardiac xenografts showed substantial metastasis, with a high metastasis to most common SCLC metastatic sites, including, lung, liver, brain, bone, ovary, adrenal, stomach, intestine, pancreas, and spleen (Fig. 4C-F). On the contrary, exogenous miR-1 overexpression markedly decreased the metastatic potential and growth of intracardially injected SBC5 cells (Fig. 4C-F). In context to most frequent metastatic sites of SCLC including lung, liver, brain, and bone [33, 34], it was observed that the intracardiac injections of SBC5 cells mimicked the metastatic properties of SCLC and validated our metastatic model to study SCLC metastasis. The key observations from the metastasis studies, clearly showed that miR-1 has the potential to decrease SCLC metastasis at the most frequent metastatic sites of SCLC, such as lung, liver, brain, and bone (Fig. 4F). In addition to the primary metastatic sites of SCLC, the endocrine organs such as the adrenal and ovary (in the case of female mice) were also reported as recurrent metastatic sites of SCLC [34–36]. The observation from metastasis studies suggests that the miR-1 overexpression decreased the adrenal and ovarian metastasis of SBC5 cells (Fig. 4C & F). Interestingly, tissue histology studies using H&E staining further suggest that miR-1 overexpression decreased the tumor burden in the most frequent metastatic sites of SCLC such as lung, liver, and brain (Fig. 4G, supplementary Fig S6-S7). Together, these findings suggest that miR-1 overexpression significantly inhibits SCLC growth and metastasis.

miR-1 modulates the CXCR4-FOXM1-RRM2 axis in SCLC

Having established the antitumorigenic potential of miR-1 in SCLC, we next examined the molecular mechanism or molecules involved in the accomplishment of the tumor-suppressive role of miR-1. We first performed a deep RNA sequencing (RNA-Seq) of SBC3, SBC3-miR-1Zip, SBC5(-DOX-off)/SBC5-DOX-On-miR-1 cells. Since SBC3 cells have a low or basal expression of miR-1 and other cells have no miR-1 expression (Fig. 1H), we performed a differentially expressed gene (DEG) analysis in SBC3, SBC3-miR-1Zip, and SBC5 cells (supplementary Fig. S8). Upon comparative analysis of the top 50 DEG in SBC3, SBC3-miR-1Zip, and SBC5 cells, we found that CXCR4 was the most differentially upregulated gene in SBC3-miR-1Zip and SBC5 cells (supplementary Fig. S8 & S9A).

CXCR4 has been previously implicated in the growth and metastasis of various cancers, including SCLC [37, 38]. Previous studies have shown that CXCR4 mediates cancer cell adhesion, migration, chemoresistance, and metastasis, and small molecule or peptide inhibitors of CXCR4 such as AMD3100, TF14016, and LY2510924 decreased tumor growth and metastasis [39–41]. In the second set of RNA-seq analysis, we performed a comparative analysis of SBC5(-DOX-off)/SBC5-DOX-On-miR-1 and SBC3/SBC3-miR-1Zip cells to assess the DEG in the presence of high miR-1 (SBC5-DOX-On-miR-1) and sponged or low miR-1 (miR-1Zip). We observed a marked downregulation of SCLC-specific gene clusters (CXCR4, RRM2, FOXM1, CCNB2, CEP55, PLK1, AURKA, AURKB, and CCNB1) in SBC5 cells overexpressing miR-1 (Fig. 5A). Interestingly, we observed upregulation or enrichment of similar gene sets (CXCR4, RRM2, FOXM1, CCNB2, CEP55, PLK1, AURKA, AURKB, CCNB1) in SBC3-miR-1Zip cells compared to SBC3 (Fig. 5B). In addition, we observed marked enrichment of CDH1 (gene encoding E-cadherin) in miR-1 overexpressing SBC5 cells, and consistent downregulation in SBC3-miR-1Zip cells (Fig. 5A-B).

Next, to investigate the tumor-suppressive mechanism of miR-1, we also performed clustering and interaction analysis of DEG (Fig. 5C-D). The clustering of DEG among miR-1 overexpressing and sponging groups suggested the existence of two to three clusters (Fig. 5C-D), solid lines connecting two members showed direct interaction within a cluster, whereas dotted line showed the interaction between the members of two clusters). Clustering analysis showed that in the first cluster, CXCR4 is shown to interact with AKT or CDH1, and in the other cluster, FOXM1 is represented as a central node for interaction with other DEG (Fig. 5C-D). FOXM1 has been previously implicated in SCLC tumorigenesis [42]. Thus, in addition to CXCR4 (the candidate gene identified in the first set of RNA-seq analysis), the clustering analysis identified FOXM1 as a second candidate gene co-operating with CXCR4, and with RRM2 a prominent downstream target of FOXM1 (Fig. 5C-D, supplementary Fig. S10-S12A). RRM2 is known to regulate DNA-damage response, cancer aggressiveness, and drug resistance, and recent studies have validated FOXM1 as a RRM2-directing transcription factor [43, 44].

We further assessed the expression status of CXCR4, FOXM1, and RRM2 in the SCLC cell line panel (SCLC-NCI, SCLC-UTSW, SCLC CCLE-Broad-MIT, SCLC GDSC-MGH-Sanger, SCLC CTRP-Broad-MIT, and SCLC Global) from the CellMiner-SCLC (https://discover.nci.nih.gov/SclcCellMinerCDB/) and observed a positive correlation in CXCR4, FOXM1, and RRM2 expression (Fig. 5E, supplementary Fig. S10-S11). In most of the SCLC cell lines, a high expression of CXCR4, FOXM1, and RRM2 showing a positive correlation, was observed (Fig. 5E, supplementary Fig. S10-S12).

To better understand the transcriptional changes caused by miR-1 inhibition or overexpression, we performed protein expression studies by immunoblotting and IHC analyses of excised tumor tissues and the results further validated the overexpression of key targets observed in the RNA-seq/clustering analysis, including (1) high CXCR4 in SBC3-miR-1Zip tumor tissues compared to SBC3 parental tumor tissues (supplementary Fig. S13B), suggesting higher metastatic signaling that was confirmed in in-vitro CXCR4 surface expression analysis and oncogenic signaling (Fig. 5F, and 6); (2) high CXCR4 mediated signaling was also validated through CXCL12 treatment in SBC3 and SBC3-miR-1Zip cells, where a comparatively high colony formation, cell migration, and AKT activation was observed in CXCL12 treated SBC3-miR-1Zip cells compared to CXCL12 untreated or parental SBC3 cells (supplementary Fig. S4 C-F); (3) high levels of proliferation, EMT, and angiogenesis-related markers (Ki67, Zeb-1, snail, and CD31) in SBC3-miR-1Zip cells and tumor tissues (Fig. 3H, Fig. 6J); (4) increased expression of FOXM1 and RRM2 in SBC3-miR-1Zip cell lines and xenografts, which was validated in protein expression studies, and direct association of FOXM1 and RRM2 was validated through a ChIP-assay (Fig. 6, supplementary Fig. S13B, S14A). To explore the impact of miR-1 on the cell surface expression of CXCR4, we performed a flow cytometry-based cell surface expression analysis of CXCR4 in SCLC cells using APC-Cy-7-anti-CXCR4 (Fig. 5F). Remarkably, it was observed that miR-1Zip increased the cell surface expression of CXCR4 in SBC3 cells (Fig. 5F). On the other hand, exogenous expression of miR-1 using the DOX-ON-miR-1 system in SBC5 and NCI-H69 cells decreased the cell surface expression of CXCR4 (Fig. 5F). These experiments demonstrate that miR-1 decreases cell surface expression of CXCR4 in SCLC cell lines. Overall, our findings suggest that miR-1-mediated modulation of CXCR4 regulates oncogenic signaling and may drive the FOXM1-RRM2 axis in SCLC.

miR-1 directly target CXCR4 and alters FOXM1 accessibility to RRM2 promoter

We next sought to identify and characterize the miR-1 targeting site in the 3'-untranslated region (3'-UTR) of CXCR4. To this end, we retrieved and cloned the 3'-UTR of CXCR4 that contained a miR-1 binding site (position 265–272 of 3'-UTR, identified using TargetScan) in the pGL3-luciferase vector (for details, see supplementary information). In another set of 3'-UTR primers, we mutated the residues of the miR-1 binding site and cloned them into the pGL3-luciferase vector. A dual-luciferase assay was performed using miR-1 mimic with wild type or mutant 3'-UTR-pGL3 constructs in SBC5 cells (as these cells have no miR-1) and found a decreased luciferase activity in SBC5 cells transfected with wild-type-3'-UTR-pGL3/miR-1 mimic compared to wild-type-3'-UTR-pGL3/scramble miR control (Fig. 6A-B). In contrast, no change in luciferase activity was observed in SBC5 cells transfected with mutant-3'-UTR-pGL3 /miR-1 mimic and mutant-3'-UTR-pGL3/scramble miR control (Fig. 6B).

To further analyze whether miR-1 directly modulates the RRM2-promotor targeting of FOXM1 we used a ChIP-coupled qPCR assay (for details see supplementary information). We found that miR-1 overexpression in SBC5 cells (DOX-On-miR-1 SBC5) decreased the enrichment of FOXM1 with RRM2-promoter (Fig. 6C), whereas an enhanced binding or enrichment of FOXM1 to the RRM2-promoter has been observed in SBC3-miR-1Zip cells compared to SBC3 parental cells (Fig. 6D). Altogether, the CXCR4 cell surface expression analysis (Fig. 5F), 3'-UTR targeting, and FOXM1-RRM2 ChIP-qPCR experiments demonstrate that miR-1 targets CXCR4 and significantly decreases the accessibility of FOXM1 to RRM2-promoter, implying that miR-1 targets the CXCR4/FOXM1-RRM2 axis in SCLC.

miR-1 targets CXCR4/FOXM1/RRM2 axis, and pharmacological inhibition of CXCR4 and FOXM1 phenocopy miR-1 efficacies

Next, we aimed to validate our transcriptional findings in SCLC cell line models and xenograft tumor tissues through protein expression studies. Consistent with the RNA-Seq data, it was observed that miR-1 sponging increased the expression of FOXM1 and RRM2 in SBC3 cells compared to parental cells (Fig. 6E). Interestingly, the ectopic expression of miR-1 in DOX-On-miR-1 -SBC5 and/or -NCI-H69 cells consistently decreased the expression of FOXM1 and RRM2 (Fig. 6F). In concordance with CXCR4 cell surface expression studies (Fig. 5F), these observations suggested that miR-1 targets CXCR4/FOXM1/RRM2 axis in SCLC.

To further establish whether CXCR4/FOXM1/RRM2 axis is a viable target of miR-1, we took advantage of AMD3100 and FDI-6, the well-characterized and highly specific small molecule inhibitors of CXCR4 and FOXM1, respectively [45, 46]. The proposed model of utilizing AMD3100 and FDI-6 has been shown in Fig. 6G. As expected, it was found that AMD3100 treatment resulted in the decreased expression of FOXM1 and RRM2 in SBC3 and SBC3-miR-1Zip cells, and the treatment of cells with FDI-6 also decreased the expression of FOXM1 and RRM2 (Fig. 6H, supplementary Fig. S14B). We followed the treatment of AMD3100 and FDI-6 in SBC5 cells and compared the expression profile of FOXM1 and RRM2 in these cells with that of SBC5 cells that ectopically overexpressed miR-1 (DOX-On-miR-1 -SBC5). Remarkably, it was observed that the treatment of SBC5 cells with either AMD3100 or FDI-6 decreased the expression of FOXM1 and RRM2, and phenocopy the consequence of miR-1 overexpression concerning FOXM1 and RRM2 expression (Fig. 6I). Additionally, to validate the relationship of FOXM1/RRM2 axis in SCLC cells, we performed genetic perturbation of FOXM1 using small interfering RNA (siRNA)-mediated knockdown in SBC5 cells and found that knockdown of FOXM1 decreased the expression of RRM2 (supplementary Fig. S14C). Furthermore, we have analyzed the expression or activation of survival and metastasis-related markers (p-AKT/AKT, p-ERK/ERK, Snail, and Zeb-1), and observed that miR-1 inhibition enhances the activation of AKT and ERK and increases the expression of snail and Zeb-1 in SBC3 cells (Fig. 6J). The overexpression of miR-1 in SBC5 and NCI-H69 cells decreases the expression of snail, and the activation of AKT and ERK (Fig. 6K). Collectively, these results suggest that miR-1 modulates CXCR4/FOXM1/RRM2 axis in SCLC, and ectopic expression of miR-1 inhibited the expression of metastasis-associated proteins (snail, Zeb-1) and activation of AKT and ERK.

To determine whether CXCR4/FOXM1/RRM2 axis or the expression pattern that we observed in RNA-Seq and in vitro SCLC models follow a similar pattern in intracardiac xenografts in vivo models or not, we performed expression analysis of CXCR4, FOXM1, and RRM2 using IHC on metastatic liver tissues (as the liver is the most frequent metastatic site of SCLC). Metastatic liver tumors revealed a high expression of CXCR4, FOXM1, and RRM2 in the tissues excised from the no-miR-1 group (SBC5-DOX-off) of mice, whereas the majority of liver tissue sections from the + miR-1 group (SBC5-DOX-On-miR-1) of mice showed very low to no expression of CXCR4, FOXM1, and RRM2 (Fig. 7A). The pathological quantification of liver tissues stained with CXCR4, FOXM1, and RRM2 further confirmed that the expression of these markers significantly decreased in the + miR-1 group (Fig. 7B). We repeated the IHC staining of CXCR4, FOXM1, and RRM2 in the liver tissues from SBC3 and SBC3-miR-1Zip intracardiac xenografts and observed intense staining of these proteins at the liver metastatic sites developed from SBC3-miR-1Zip cells, and in contrast, no staining was observed in SBC3 injected group (Fig. 7C-D). Taken together, the IHC-analysis supports that miR-1 directs the CXCR4/FOXM1/RRM2 axis in SCLC.

SCLC xenografts derive greater survival benefits from high miR-1

Given that miR-1 loss aggravates SCLC growth and metastasis, whereas exogenous overexpression of miR-1 decreased the metastatic proficiencies of SCLC cells (Fig. 3–4), we next asked whether miR-1 has any effect on the overall survival of mice bearing SCLC tumors. Therefore, to explore the clinical implications of miR-1 in terms of survival, we again performed intracardiac injections of DOX-On-miR-1 SBC5 cells in NSG mice and looked for the establishment of metastasis using IVIS-imaging. The animals were randomized into (+)miR-1/+DOX and (-)miR-1/-DOX groups. Strikingly, miR-1 expression significantly prolonged the survival of mice standing intracardiac SCLC xenografts compared to the no miR-1 group (Fig. 7E). The estimated median survival was nearly 65 days for the + miR-1 group, whereas it was only 34 days for the without miR-1 group (Fig. 7E). Next, we explored the possibility of detecting miR-1 levels in the serum of mice intracardially injected with SCLC cells using the DNA-AuNPs nanoprobe-mediated detection assay we developed (Fig. 1E). Interestingly, a significantly high miR-1 level was observed in the serum samples of mice showing prolonged survival (Fig. 7F). Collectively, this data shows that miR-1 provided survival benefits in vivo as it promotes the survival of mice injected with SCLC cells and decreased tumorigenesis and metastasis.

SCLC is one of the most aggressive types of cancer with proven challenges of limited therapeutic options. Based on its coherent histology, SCLC was classically considered as a homogenous tumor type and remained a ‘poster child’ disease; however, recent studies involving the compilation of high throughput transcriptomic approaches established that SCLC represents a highly dynamic cancer type with high levels of subtype switching and plasticity [47–49]. In comparison with other cancers, the DNA and RNA sequencing studies of SCLC tumors identified a limited number of actionable therapeutic targets or molecules that may be applied to patients, and owing to high neuroendocrine (NE) and/or non-NE intratumoral plasticity, these limited options present a challenge in the generation of personalized therapies. Thus, there remains an imperative need to identify novel therapeutic molecules or targets that can improve SCLC outcomes.

In this study, using bioinformatics analysis of publicly available datasets, human tissues, cell lines, and serum analysis, we identified miR-1 as an important tumor suppressor gene in SCLC. The mature single MiR-1 is encoded by two separate genes, MIR-1-1 and MIR-1-2 located on the separate chromosomal loci (20q13.33 and 18q11.2, respectively) [18, 20]. The role of miR-1 has been well described in cardiomyocytes and skeletal muscle precursor cells [18]. It regulates the differentiation of smooth muscle cells, innate immune response, glucose-mediated apoptosis, and proliferation and invasion of gastric cancer cells through transforming growth factor-beta signaling [50–52]. Interestingly, the serum signature of miR-1 was reported as a prognostic factor in NSCLC [53]. Using a noninvasive serum transcriptomic-based and nanoprobe-mediated detection system for miR-1, we find low serum miR-1 in SCLC patients compared to healthy donors and equally observe low or null miR-1 expression in human SCLC tumor tissues compared to normal lung tissues. In addition, our in vivo studies showed a survival benefit in the mice bearing intracardiac xenografts having high miR-1 levels. The median survival of mice with high miR-1 is nearly two-fold higher than the low miR-1 group, thus, identifying low miR-1 as a hallmark of SCLC.

Of interest, SCLC is considered a metastatic disease, accounting for ~ 70% of patients who show distant metastasis at the time of diagnosis [34]. CXCR4 is a well-characterized chemokine receptor that regulates cancer metastasis, including SCLC metastasis [37–40]. The inhibition of CXCR4 using small molecule inhibitors suppressed the SCLC metastasis in vivo [39]. Interestingly, we observed miR-1 directly targets 3'-UTR of CXCR4 in SCLC cell lines. Our mechanistic studies revealed that miR-1 is associated to modulate CXCR4 expression in SCLC cells and the metastatic lesions of intracardiac xenografts. Our data also suggest that miR-1 mediated CXCR4 modulations require FOXM1 pathway activity to promote tumor growth and metastasis. Our observations from miR-1 overexpression or knockdown cell line models suggest that miR-1 targets the CXCR4/FOXM1 axis; therefore, it is critical that we better define miR-1 modulatory effects on CXCR4/FOXM1 axis. Moreover, we confirmed these results with AMD3100, a highly specific small-molecule inhibitor of CXCR4. Inhibition of CXCR4 using AMD3100 decreased the expression of FOXM1, demonstrating that FOXM1 is downstream of CXCR4 inhibition that results in FOXM1 suppression.

FOXM1 is a transcription factor that belongs to the Forkhead superfamily, with a highly conserved (winged helix) DNA-binding domain and plays an essential role in the regulation of a plethora of biological mechanisms, including cell cycle regulation, angiogenesis, cell proliferation, DNA damage repair, and apoptosis [54, 55]. Studies suggest that tumor suppressor p53 is required for FOXM1 downregulation that follows a retinoblastoma (Rb) dependent mechanism [56]. In context to frequent deletion or loss of function mutations in TP53 and RB1 [7, 8], and consistent with a recent report that shows a crucial role of FOXM1 using Rb1^fl/fl; Trp53^fl/fl; Lox-Stop-Lox [LSL]-Myc^T58A (RPM) models and patient samples in SCLC tumorigenesis and poor clinical prognosis [42], our work builds an agreement that miR-1 mediated downregulation of CXCR4/FOXM1 axis could be a major event regulating SCLC growth and metastasis. In addition, two independent studies in SCLC suggest that high FOXM1 and CXCR4 decrease the overall survival of SCLC patients compared to the low FOXM1/CXCR4 group [42, 57]. Consistent with the previous studies that showed FOXM1 is regulated in a p53 and Rb/E2F dependent manner, our data suggest that miR-1 overexpression downregulated most of the SCLC specific gene signatures that were overexpressed due to TP53 and RB1 inactivation or FOXM1 overexpression such as PLK1, CENPA, AURKA, AURKB, CCNB2, CCNB1, CEP55, CXCR4, and RRM2 [56, 58, 59], while miR-1 inactivation increased their expression.

Notably, we observed that miR-1 overexpression decreased the expression of RRM2, while miR-1 sponging increased RRM2 expression. RRM2 is a reductase that catalyzes the conversion of ribonucleotides to deoxyribonucleotides, protects cancer cells from replication stress, induces drug resistance, regulates purine metabolism, cell cycle, and DNA repair [60, 61]. Our unbiased RNA-Seq and clustering data identified RRM2 as a major target gene regulated by FOXM1 in SCLC. Using genetic and pharmacological tools, we demonstrated that inhibition of FOXM1 decreases RRM2 expression in SCLC cell lines. We envisage that in SCLC cells, FOXM1 might have direct interactions with the promoter region of RRM2. Our ChIP assay established that FOXM1 has an affinity for the promoter region of RRM2 and miR-1 modulates the binding of FOXM1 with the RRM2 promoter. An interesting study has been demonstrated recently that FOXM1 transcriptionally activates RRM2 in prostate cancer [43]. RRM2 has been implicated in epithelial to mesenchymal transition (EMT) and tumor-associated angiogenesis [58, 59]. Consistent with this, we observed a significant downregulation of EMT markers (Zeb-1, Snail) in miR-1 overexpressing SCLC cell lines, and upregulation of these EMT markers along with CD31 (a marker of angiogenesis) had been observed in miR-1 knockdown conditions. In transcriptomics studies, we found the enrichment of CDH1 (E-cadherin) in miR-1 overexpressing cell lines, whereas miR-1 knockdown is coupled with a decrement in CDH1. Furthermore, we demonstrated the dependency of the CXCR4/FOXM1 axis on RRM2, though it remains possible that FOXM1 may directly influence other targets of SCLC, for example, AURK(A/B) and PLK1. However, taken together, the outcomes of the gene enrichment study, ChIP-assay, pharmacological inhibition of CXCR4 and FOXM1, or genetic knockdown of FOXM1 establish that miR-1 modulates the CXCR4/FOXM1/RRM2 axis in SCLC cells (Fig. 7G).

Progressively, the recent studies are identifying subtype-specific unique and viable therapeutic vulnerabilities for SCLC; for example, NOTCH activation, inhibition of AURKA/B, LSD1, HDAC, BET, and EZH2 [62–66]. Our work builds an interesting concept where it implicates the outcomes of the present study to develop a potential therapeutic window for the activation/overexpression of miR-1 to inhibit SCLC or targeted delivery of miR-1 using alternative approaches such as nanoparticle-mediated delivery of small RNA/DNA molecules. While the utilization of miRNAs as inhibitors or activators is still in the developing stages and needs to be further improved or developed to cope with the undesired or off-target effects; however, our efforts also highlight the possibilities of targeting the CXCR4/FOXM1/RRM2 axis to thwart SCLC growth and metastasis (Fig. 7G).

In summary, our findings revealed that miR-1 is a critical regulator for SCLC growth and metastasis. Owing to the antitumorigenic role of miR-1 in SCLC, our results provided a novel mechanistic insight that revealed that miR-1 targets CXCR4/FOXM1/RRM2 axis that attenuates SCLC growth and metastasis. This study provided an understanding of the role of miR-1 in SCLC and rationalized the therapeutic targeting of the CXCR4/FOXM1/RRM2 axis or individual members of this axis for the development of novel SCLC therapies. In addition, we have developed a highly sensitive nanoprobe-mediated noninvasive miR-1 detection method that could be utilized in future diagnostic tools for miR-1 or can be optimized for the detection of other miRNAs. These findings further provided a platform for utilizing serum miR-1 levels as a potential biomarker or future noninvasive predictor for the survival and prognosis of this devastating disease.

Non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), RNA interference (RNAi), microRNAs (miRNAs), Cadherin 1 (CDH1), RNA-induced silencing complex (RISC), microRNA-1-3p (miR-1), Chemokine (C-X-C Motif) receptor 4 (CXCR4), Forkhead box protein M1 (FOXM1), Differentially expressed genes (DEG), Ribonucleotide reductase regulatory subunit M2 (RRM2), transmission electron microscopy (TEM), in situ hybridization (ISH), DNA-probe-modified Au-nanoparticles (DNA-AuNPs).

Ethics approval and consent to participate

All mouse experiments/procedures were duly approved and performed as per Institutional animal care and use committee (IACUC) guidelines in accordance with the National Institute of Health (NIH). The animals were maintained as per IACUC guidelines in the University of Nebraska medical center (UNMC) animal house facility (IACUC # 17-045-06-FC).

Consent for publication

All authors agree with the content of the manuscript and consent to publication.

Competing interests

SKB is co-founder of Sanguine Diagnostics and Therapeutics, Inc. AKG has served on Advisory Boards for AstraZeneca, Jazz pharmaceuticals, Sanofi–Genzyme, Beigene; received research support from Takeda Pharmaceuticals, Merck, TAB Biosciences, IOVANCE, and Mirati Therapeutics; is a consultant for Flagship Biosciences and serves on the DSMC for Y-mAbs Therapeutics. Other authors declare no competing interests.

Availability of data and materials

The data supporting the results and conclusions of this article are included in this article and its supplementary files. The RNA-Sequencing data generated in this study were deposited to GEO repository with accession number GSE00000 and will be available publicly following the publication of this article.

Funding

Lung cancer studies in our laboratory are supported by the National Institutes of Health (NIH) grants R01CA218545 and R01CA241752-01A1 to MWN. The work of M.J. and SKB are supported by NIH R01CA247471, R01CA195586, and P01 CA217798. The work of RS is supported by the National Cancer Institute of NIH under award numbers P30CA033572, U54CA209978, R01CA247471, and R01CA218545.

Author’s contributions

PK and MWN were involved in the conception and design of the experiments. MWN supervised the study. PK performed the study and wrote the original draft of the manuscript. JAS helped in the intracardiac injections and mice studies. PGK performed nanoparticle-related studies. RCV analyzed RNA-seq data. SKM, TM, NKP, SC, RKK, MF, MAK, and AUR helped in performing the experiments. GAT performed histological analysis. IL, SM, PK, MJ, AKG, RS, SKB, and MWN critically revised the manuscript and provided scientific feedback. All authors read and approved the content of the manuscript before final submission.

Acknowledgements

We thank our colleagues for their valuable suggestions, critical reading, and useful comments on the preparation of this manuscript. Model illustrations were created with BioRender.com.

George, J., et al., Comprehensive genomic profiles of small cell lung cancer. Nature, 2015. 524(7563): p. 47–53.
van Meerbeeck, J.P. and D. Ball, Small-cell lung cancer: local therapy for a systemic disease? Lancet, 2015. 385(9962): p. 9–10.
van Meerbeeck, J.P., D.A. Fennell, and D.K. De Ruysscher, Small-cell lung cancer. Lancet, 2011. 378(9804): p. 1741–55.
Li, L., et al., Identification of DHODH as a therapeutic target in small cell lung cancer. Sci Transl Med, 2019. 11(517).
Byers, L.A. and C.M. Rudin, Small cell lung cancer: where do we go from here? Cancer, 2015. 121(5): p. 664–72.
Chung, H.C., et al., Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol, 2020. 15(4): p. 618–627.
Rudin, C.M., et al., Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet, 2012. 44(10): p. 1111–6.
Peifer, M., et al., Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet, 2012. 44(10): p. 1104–10.
Djebali, S., et al., Landscape of transcription in human cells. Nature, 2012. 489(7414): p. 101–8.
Ambros, V., The functions of animal microRNAs. Nature, 2004. 431(7006): p. 350–5.
Bartel, D.P., MicroRNAs: target recognition and regulatory functions. Cell, 2009. 136(2): p. 215–33.
Krek, A., et al., Combinatorial microRNA target predictions. Nat Genet, 2005. 37(5): p. 495–500.
Olson, P., et al., MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev, 2009. 23(18): p. 2152–65.
Kozomara, A., M. Birgaoanu, and S. Griffiths-Jones, miRBase: from microRNA sequences to function. Nucleic Acids Res, 2019. 47(D1): p. D155-D162.
Sun, K. and E.C. Lai, Adult-specific functions of animal microRNAs. Nat Rev Genet, 2013. 14(8): p. 535–48.
Kloosterman, W.P. and R.H. Plasterk, The diverse functions of microRNAs in animal development and disease. Dev Cell, 2006. 11(4): p. 441–50.
Ambros, V., The functions of animal microRNAs. Nature, 2004. 431(7006): p. 350–355.
Zhao, Y., E. Samal, and D. Srivastava, Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature, 2005. 436(7048): p. 214–20.
Chen, J.F., et al., The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet, 2006. 38(2): p. 228–33.
Khan, P., et al., MicroRNA-1: Diverse role of a small player in multiple cancers. Semin Cell Dev Biol, 2021.
Wang, W., et al., Label-Free MicroRNA Detection Based on Fluorescence Quenching of Gold Nanoparticles with a Competitive Hybridization. Anal Chem, 2015. 87(21): p. 10822–9.
Arroyo, J.D., et al., Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A, 2011. 108(12): p. 5003–8.
Siddiqui, J.A., et al., GDF15 promotes prostate cancer bone metastasis and colonization through osteoblastic CCL2 and RANKL activation. Bone Res, 2022. 10(1): p. 6.
Karmakar, S., et al., RNA Polymerase II-Associated Factor 1 Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions With PHF5A and DDX3. Gastroenterology, 2020. 159(5): p. 1898–1915 e6.
Chaudhary, S., et al., overexpression of caspase 7 is ERalpha dependent to affect proliferation and cell growth in breast cancer cells by targeting p21(Cip). Oncogenesis, 2016. 5: p. e219.
Kanchan, R.K., et al., MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3). Brain Pathol, 2020. 30(4): p. 732–745.
Wang, Z., et al., The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin. Mol Cancer, 2022. 21(1): p. 29.
Khan, P., et al., RNA-based therapies: A cog in the wheel of lung cancer defense. Mol Cancer, 2021. 20(1): p. 54.
Zhang, B., et al., m(6)A target microRNAs in serum for cancer detection. Mol Cancer, 2021. 20(1): p. 170.
Geekiyanage, H., et al., Extracellular microRNAs in human circulation are associated with miRISC complexes that are accessible to anti-AGO2 antibody and can bind target mimic oligonucleotides. Proc Natl Acad Sci U S A, 2020. 117(39): p. 24213–24223.
Datta, J., et al., Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res, 2008. 68(13): p. 5049–58.
Bronisz, A., et al., Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Cancer Res, 2014. 74(3): p. 738–750.
Rudin, C.M., et al., Small-cell lung cancer. Nat Rev Dis Primers, 2021. 7(1): p. 3.
Ko, J., M.M. Winslow, and J. Sage, Mechanisms of small cell lung cancer metastasis. EMBO Mol Med, 2021. 13(1): p. e13122.
Kitazawa, J., et al., Small-cell lung carcinoma with ovarian metastasis 4 years after the first-line treatment. Int Cancer Conf J, 2019. 8(3): p. 109–113.
Sharma, S.K., et al., Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Res, 2017. 77(14): p. 3931–3941.
Kijima, T., et al., Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res, 2002. 62(21): p. 6304–11.
Burger, M., et al., Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene, 2003. 22(50): p. 8093–101.
Otani, Y., et al., Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016. FEBS Lett, 2012. 586(20): p. 3639–44.
Hartmann, T.N., et al., CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene, 2005. 24(27): p. 4462–71.
Salgia, R., et al., A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. Lung Cancer, 2017. 105: p. 7–13.
Liang, S.K., et al., FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis. Oncogene, 2021. 40(30): p. 4847–4858.
Mazzu, Y.Z., et al., A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res, 2019. 25(14): p. 4480–4492.
Xiong, W., et al., RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway. Adv Sci (Weinh), 2021. 8(18): p. e2100881.
Gormally, M.V., et al., Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat Commun, 2014. 5: p. 5165.
Joao, H.C., et al., Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. J Med Chem, 1995. 38(19): p. 3865–73.
Rudin, C.M., et al., Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer, 2019. 19(5): p. 289–297.
Chan, J.M., et al., Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell, 2021. 39(11): p. 1479–1496 e18.
Mahadevan, N.R., et al., Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov, 2021. 11(8): p. 1952–1969.
Ke, J., et al., MiR-1-3p suppresses cell proliferation and invasion and targets STC2 in gastric cancer. Eur Rev Med Pharmacol Sci, 2019. 23(20): p. 8870–8877.
Shan, Z.X., et al., miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FEBS Lett, 2010. 584(16): p. 3592–600.
Xu, H., et al., Inducible degradation of lncRNA Sros1 promotes IFN-gamma-mediated activation of innate immune responses by stabilizing Stat1 mRNA. Nat Immunol, 2019. 20(12): p. 1621–1630.
Hu, Z., et al., Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol, 2010. 28(10): p. 1721–6.
Laoukili, J., et al., FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol, 2005. 7(2): p. 126–36.
Korver, W., J. Roose, and H. Clevers, The winged-helix transcription factor Trident is expressed in cycling cells. Nucleic Acids Res, 1997. 25(9): p. 1715–9.
Barsotti, A.M. and C. Prives, Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene, 2009. 28(48): p. 4295–305.
Salgia, R., et al., Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. Invest New Drugs, 2017. 35(3): p. 334–344.
Millour, J., et al., ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther, 2011. 10(6): p. 1046–58.
Oser, M.G., et al., Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov, 2019. 9(2): p. 230–247.
D'Angiolella, V., et al., Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell, 2012. 149(5): p. 1023–34.
Rasmussen, R.D., et al., BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity. Nat Commun, 2016. 7: p. 13398.
Mohammad, H.P., et al., A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell, 2015. 28(1): p. 57–69.
Augert, A., et al., Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Sci Signal, 2019. 12(567).
Jia, D., et al., Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov, 2018. 8(11): p. 1422–1437.
Khan, P., et al., Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. Semin Cancer Biol, 2020.
Gardner, E.E., et al., Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. Cancer Cell, 2017. 31(2): p. 286–299.

Competing interest reported. SKB is co-founder of Sanguine Diagnostics and Therapeutics, Inc. AKG has served on Advisory Boards for AstraZeneca, Jazz pharmaceuticals, Sanofi–Genzyme, Beigene; received research support from Takeda Pharmaceuticals, Merck, TAB Biosciences, IOVANCE, and Mirati Therapeutics; is a consultant for Flagship Biosciences and serves on the DSMC for Y-mAbs Therapeutics. Other authors declare no competing interests.

Download PDF

Journal Publication

published 04 Jan, 2023

Read the published version in Molecular Cancer →

Editorial decision: Major revision
25 May, 2022
Reviews received at journal
23 May, 2022
Reviewers agreed at journal
09 May, 2022
Reviews received at journal
25 Apr, 2022
Reviewers agreed at journal
19 Apr, 2022
Reviewers invited by journal
18 Apr, 2022
Editor assigned by journal
12 Apr, 2022
Submission checks completed at journal
12 Apr, 2022
First submitted to journal
08 Apr, 2022

You are reading this latest preprint version

MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis

Status:

Journal Publication

Version 1

Abstract

Figures

Background

Material And Methods

Cell lines and maintenance

DNA-AuNPs nanoprobe for the detection of miR-1 in serum and cell lines

In-situ hybridization

Lentivirus production

Generation of miR-1 inducible and miR-1Zip system

Small RNA library preparation and miRNA sequencing from serum samples of SCLC patients

RNA-sequencing and deferential gene expression analysis

Chromatin immunoprecipitation and qPCR

CXCR4 3'-UTR dual luciferase assay

SCLC cell line xenografts studies

a) SBC3 and SBC3-miR-1Zip cells

b) miR-1 inducible SBC5 cells

Survival studies

Statistical analysis

Results

Overall microRNA expression landscape in SCLC identifies miR-1 as a tumor suppressor gene in SCLC

miR-1 modulates tumor growth and metastasis in SCLC xenografts

miR-1 modulates the CXCR4-FOXM1-RRM2 axis in SCLC

miR-1 directly target CXCR4 and alters FOXM1 accessibility to RRM2 promoter

miR-1 targets CXCR4/FOXM1/RRM2 axis, and pharmacological inhibition of CXCR4 and FOXM1 phenocopy miR-1 efficacies

SCLC xenografts derive greater survival benefits from high miR-1

Discussion

Conclusions

Abbreviations

Declarations

References

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1